Introduction {#s1}
============

Alcoholic liver disease (ALD) remains to be one of the most common etiologies of liver diseases and is a major cause of morbidity and mortality worldwide [@pone.0054188-Zeng1]. The burden of ALD is highest in the developed world, where it may account for as much as 9.2% of all disability-adjusted life years [@pone.0054188-OShea1]. Although the progression of ALD has been well-characterized, there is no universally accepted therapy available to halt or reverse this process in humans [@pone.0054188-Beier1]. At present, the underlying mechanisms of ALD are still not fully understood, however, oxidative stress has been demonstrated to play important roles [@pone.0054188-Cederbaum1]. With better understanding of the mechanisms and risk factors that mediate the initiation and progression of ALD, rational targeted therapy can be developed to treat or prevent ALD. It has been demonstrated that a clear correlation exists between cumulative alcohol intake and ALD; however, only a small portion of the alcohol abusers develop signs of liver disease, which suggests some of the genetic variations are involved in the etiology of ALD [@pone.0054188-Monzoni1].

Cytochrome P4502E1 (CYP2E1) is a member of the phage I detoxifying enzymes, which plays important roles in the metabolic activation of many xenobiotics including alcohol. CYP2E1 is physiologically responsible for about 10% of ethanol metabolism, but it could be induced after chronic ethanol administration [@pone.0054188-Zeng2], [@pone.0054188-SanchezCatalan1]. Accumulating evidence has demonstrated that CYP2E1 activation may play crucial roles in the etiology of ALD, which might be related with overproduction of reactive oxygen species (ROS) and the enhancement of the lipid peroxidation [@pone.0054188-Zeng1], [@pone.0054188-Lu1], [@pone.0054188-Lu2]. Therefore, it is plausible that functional polymorphisms in *CYP2E1* gene might be related with the risk of ALD in individuals.

*CYP2E1*, located in 10q2403-qter, is a 1104 kb gene consisting of 9 exons and 8 introns. *CYP2E1* contains six restriction fragment length polymorphisms (RFLP), among which the *Pst I/Rsa I* polymorphism in its 5′-flanking region was reported to be associated with higher transcription and increased enzyme activity [@pone.0054188-Hayashi1]. Another polymorphism detectable with *Dra I* in intron 6 is also known to be associated with increased expression and enzyme activity [@pone.0054188-Parsian1]. The associations between the above two *CYP2E1* gene polymorphisms and the risks of ALD have been widely investigated in the past 20 years. Unfortunately, these epidemiological studies have yielded conflicting results, which might be related with the ethnic difference in the distribution of the mutant alleles and the relatively small sample size in some studies underpowered to detect the potential effects. Considering the important roles of CYP2E1 in the etiology of ALD, it would be necessary to summarize all these individual studies and discern whether *CYP2E1* gene polymorphisms are associated with the risks of ALD. Thus, we performed a meta-analysis in order to provide more accurate estimate of the association of the above gene polymorphisms and the risks of ALD.

Materials and Methods {#s2}
=====================

Literature and Search Strategy {#s2a}
------------------------------

A computerized literature search was conducted for the relevant available studies from 3 databases including PubMed, ISI Web of Science, and Embase. The search strategy to identify all possible studies involved use of combinations of the following key words: ("cytochrome P450 2E1" or "CYP2E1") and "polymorphism" and ("alcohol" or "ethanol") and ("alcoholic liver disease" or "ALD" or "alcoholic fatty liver" or "steatosis" or "hepatitis" or "fibrosis" or "cirrhosis"). The reference lists of review articles, clinical trials, and meta-analyses were also hand-searched to identify additional works. There was no restriction on time period, sample size, population, language, or type of reports. If more than one article were published using the same case series, only the study with largest sample size was selected. The literature search was updated to June 2012.

Inclusion Criteria {#s2b}
------------------

The studies included must meet the following criteria: (1) evaluating the association between *CYP2E1 Pst I/Rsa I and/or Dra I* polymorphisms and the risk of ALD; (2) providing sufficient data for calculation of odds ratio (OR) with the corresponding 95% confidence interval (95%CI). When genotype frequencies and OR with 95%CI were all not available, authors were contacted to request the relevant information. All identified studies were carefully reviewed independently by two investigators to determine whether an individual study was eligible for inclusion in this meta-analysis.

Data Extraction {#s2c}
---------------

Data were extracted independently by two investigators who reached a consensus on all of the items. The following information was extracted from each study: (1) name of the first author; (2) year of publication; (3) country of origin; (4) ethnicity of the study population; (5) numbers of cases and controls; (6) gender and age of enrolled subjects; and (7) numbers of genotypes in cases and controls.

Statistical Analysis {#s2d}
--------------------

The associations between *CYP2E1 Pst I/Rsa I and/or Dra I* polymorphisms and ALD risks were estimated by calculating pooled ORs and 95%CI. The comparisons were made between ALD patients and alcoholics without ALD, and between ALD patients and non-alcoholics without liver diseases (non-alcoholics), respectively. The significance of the pooled effect size was determined by *Z* test. χ2 analysis with exact probability was used to test departure from Hardy-Weinberg equilibrium (HWE) for the genotype distribution in control groups (non-alcoholics). Heterogeneity among studies was assessed by χ^2^-based Q test as well as the *I^2^* statistic [@pone.0054188-Higgins1]. A significant Q-statistic (*P \<* 0.10) indicated heterogeneity across studies. Subgroup analyses were performed based on the ethnicity of the enrolled subjects, the type of ALD, and the gender of subjects. Sensitivity analysis was undertaken by removing one individual study each time to check whether any of single study could bias the overall estimate [@pone.0054188-Tobias1]. An individual study was suspected of excessive influence, if the point estimate of its omitted analysis lies outside of the 95%CI of the combined analysis. Begg's funnel plots and Egger's regression test were undertaken to assess the potential publication bias. Probability less than 0.05 was judged significant except for the *I* ^2^ statistic. Data analysis was performed using STATA version 11 (StataCorp LP, College Station, Texas, USA).

Results {#s3}
=======

Characteristics of Studies {#s3a}
--------------------------

The flowchart of the study selection for this meta-analysis was shown in the [**Figure 1**](#pone-0054188-g001){ref-type="fig"}. As shown in [**Figure 1**](#pone-0054188-g001){ref-type="fig"}, a total of 69 studies were identified through database searching, and 40 studies were excluded for various reasons. Finally, 27 [@pone.0054188-Monzoni1], [@pone.0054188-Parsian1], [@pone.0054188-Liu1]--[@pone.0054188-IngelmanSundberg1] and 9 studies [@pone.0054188-Parsian1], [@pone.0054188-Lorenzo1], [@pone.0054188-Vidal1], [@pone.0054188-Frenzer1], [@pone.0054188-Wong1], [@pone.0054188-Lucas1], [@pone.0054188-IngelmanSundberg1]--[@pone.0054188-Savolainen1] were included in the meta-analyses for the associations between the *CYP2E1 Pst I/Rsa I* polymorphism and the risks of ALD, and *CYP2E1 Dra I* polymorphism and the risks of ALD, respectively. All these included studies used peripheral blood samples for DNA extraction and polymerase chain reaction-restriction fragment length polymorphism (PCR-RELP) methods for genotyping. These studies were performed in a wide range of geographical settings leading to a diversity of racial groups. For the *Pst I/ Rsa I* polymorphisms, 9 studies examined individuals of Asians, 15 studies recruited Caucasians, one study in Brazilian [@pone.0054188-Burim1], one study in Indian [@pone.0054188-Khan1], and one study in Mexican [@pone.0054188-GarciaBanuelos1]. For the *Dra I* polymorphism, all the studies were on Caucasians. In these studies, the genotype/allele distribution between ALD patients and the alcoholics without ALD, and/or between ALD patients and non-alcoholics, were compared. The detailed characteristics of the included studies were shown in the [**Table 1**](#pone-0054188-t001){ref-type="table"} **and** [**Table 2**](#pone-0054188-t002){ref-type="table"} **, respectively.** The detailed criteria for the selection of ALD patients, alcoholics without ALD, and non-alcoholics were shown in **[Table S1](#pone.0054188.s001){ref-type="supplementary-material"}**.

![Flow chart of study selection based on the inclusion and exclusion criteria.](pone.0054188.g001){#pone-0054188-g001}
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###### Characteristics of individual studies for association between *CYP2E1 Pst I/Rsa I* polymorphisms and ALD risks.

![](pone.0054188.t001){#pone-0054188-t001-1}

  Study                                            Country     Age[b](#nt103){ref-type="table-fn"}      Sex      Type of ALD    Cases   Alcoholics without ALD   Non-alcoholics   *P* ~HWE~ [d](#nt105){ref-type="table-fn"}                            
  ---------------------------------------------- ----------- ---------------------------------------- -------- --------------- ------- ------------------------ ---------------- -------------------------------------------- ---- ---- ----- ---- ---- -------
  Liu,2012                                          China                    51/na/na                   Both    AC/AH/AFL/HCC    203             106                   44                            271                       19   10   325   24   11   0.000
  Garcia-Banuelos,2012                             Mexico                     44/42                     Both         AC          25               16                   0                                                                 73    15   2    0.266
  Khan,2010                                         India                    52/48/42                    na          AC          161              14                   0                             137                       3    0    250   5    0    0.874
  Lorenzo,2006                                      Spain                    55/54/48                  Female     AC/AH/AFL      53               2                    3                              27                       0    0    40    2    0    0.874
  Cichoz-Lach,2006                                 Poland                    50/44/51                   Both         AC          53               4                    0                              43                       0    0    54    0    0     na
  Vidal,2004                                        Spain                    53/57/46                   Male      AC/AH/AFL      94               5                    0                              42                       4    1    57    7    0    0.644
  Kim,2004                                          Korea                     49/49                     Both         AC          17               4                    0                                                                 51    34   15   0.029
  Burim,2004                                       Brazil     18--76[c](#nt104){ref-type="table-fn"}    Both         AC          59               6                    0                              37                       4    0    197   23   1    0.712
  Kee,2003                                          Korea                       na                       na          AC          17               10                   3                              4                        7    1    23    15   0    0.130
  Frenzer,2002                                    Australia                  58/42/50                   Both         AC          56               1                    0                              54                       3    0    188   12   0    0.662
  Monzoni,2001                                      Italy                     58/58                     Both      AC/AH/AFL      66               14                   1                              85                       7    0                     na
  Lee,2001                                          Korea                    52/52/50                   Male         AC          34               21                   1                              32                       19   1    41    22   1    0.305
  Zhang,2000                                        China      52.3[c](#nt104){ref-type="table-fn"}     Male      AC/AH/HCC       2               50                   3                                                                 17    9    0    0.286
  Wong,2000                                          UK       18--90[c](#nt104){ref-type="table-fn"}    Both      AH/AF/AC       59               2                    0                                                                 350   25   0    0.504
  Rodrigo,1999                                      Spain                    55/60/45                   Male         AC          112              8                    0                              28                       2    0    183   17   0    0.530
  Parsian,1998[a](#nt102){ref-type="table-fn"}       USA                        na                      Both         AC                                                                                                                                   na
  Grove,1998                                         UK                         na                      Both      AC/AF/AH       226              14                   0                                                                 117   4    0    0.853
  Tanaka,1997                                       Japan                      49/-                     Male      AC/AF/AH       13               9                    4                              30                       11   1                     na
  Chao,1997                                         China                    51/50/22                   Both         AC          42               29                   4                              12                       5    2    56    38   6    0.894
  Lucas,1996                                       France                 55/44/(20--50)                 na          AC          101              9                    0                             188                       12   2    248   11   1    0.033
  Carr,1996                                         China                    55/40/20                    na          AC          18               10                   2                              28                       18   0    52    45   3    0.065
  Agundez,1996                                      Spain                     54/32                     Both         AC          56               2                    0                                                                 130   7    0    0.789
  Yamauch,1995                                      Japan                   (38--70)/-                  Male         AC          34               12                   0                                                                 40    18   2    0.989
  Pirmohamed,1995                                    UK                         na                      Both        AC/AH        77               17                   1                              55                       2    1    97    3    0    0.879
  Carr,1995                                          USA                   (33--72)/-/-                 Male        AC/AH        49               3                    1                              35                       4    0    31    1    0    0.929
  Ball,1995                                          UK                         na                       na          AC          34               3                    0                                                                 102   6    0    0.767
  Ingelman-Sundberg,1993                            Italy                       na                       na          AC          53               30                   0                                                                 104   10   0    0.624

Abbreviations: ALD, alcoholic liver disease; AC, alcoholic cirrhosis; AH, alcoholic hepatisis; AFL, alcoholic fatty liver; AF, alcoholic fibrosis; HCC, hepatic carcinoma.

the study by Parsian did not provide the number of each genotypes, instead they provided the number of alleles of case and controls;

the mean age and/or the range of age of each groups;

cases and controls combined;

*p* for Hardy--Weinberg equilibrium test in controls (Healthy person);

"na", means that the data were not available.

10.1371/journal.pone.0054188.t002

###### Characteristics of individual studies for association between *CYP2E1 Dra I* polymorphisms and ALD risks.

![](pone.0054188.t002){#pone-0054188-t002-2}

  Study                                            Country      Age[b](#nt109){ref-type="table-fn"}      Sex     Type ofALD   Cases   Alcoholics without ALD   Non-alcoholics   *P* ~HWE~ [d](#nt111){ref-type="table-fn"}                          
  ---------------------------------------------- ----------- ----------------------------------------- -------- ------------ ------- ------------------------ ---------------- -------------------------------------------- ---- --- ----- ---- --- -------
  Khan,2009                                         India                    52/49/42                     na         AC        118              42                   0                              67                       33   0   182   68   0   0.013
  Lorenzo,2006                                      Spain                    55/54/48                   Female   AC/AH/AFL     36               22                   0                              18                       9    0   34    8    0   0.495
  Vidal,2004                                        Spain                    53/57/46                    Male    AC/AH/AFL     75               23                   1                              36                       11   0   45    18   1   0.594
  Frenzer,2002                                    Australia                  58/42/50                    Both        AC        48               9                    0                              46                       10   1   170   28   2   0.489
  Wong,2000                                          UK       18--90[c](#nt110){ref-type="table-fn"}     Both     AH/AF/AC     50               11                   0                                                                305   68   2   0.386
  Parsian,1998[a](#nt108){ref-type="table-fn"}       USA                        na                       Both        AC                                                                                                                               na
  Savolainen,1997                                  Finland    35--69 [c](#nt110){ref-type="table-fn"}    Male     AH/AF/AC     156              48                   3                              30                       6    0                   na
  Lucas,1996                                       France                 55/44/(20--50)                  na         AC        79               30                   1                             149                       49   4   219   37   2   0.752
  Ingelman-Sundberg,1993                            Italy                       na                        na         AC        47               4                    0                                                                95    19   0   0.332

Abbreviations: ALD, alcoholic liver disease; AC, alcoholic cirrhosis; AH, alcoholic hepatisis; AFL, alcoholic fatty liver; AF, alcoholic fibrosis; HCC, hepatic carcinoma.

the study by Parsian did not provide the number of each genotypes, instead they provided the number of alleles of case and controls;

the mean age and/or the range of age of each groups;

cases and controls combined;

*p* for Hardy--Weinberg equilibrium test in controls (Healthy person);

"na", means that the data were not available.

Quantitative Data Synthesis {#s3b}
---------------------------

Results of pooled analysis on the associations between *CYP2E1 Pst I/Rsa I* polymorphism and the risk of ALD were shown in **[Table S1](#pone.0054188.s001){ref-type="supplementary-material"}**. Overall, no significant association between c2 allele and the risks of ALD was observed (ALD patients *vs.* alcoholics without ALD: OR = 1.52, 95%CI 0.94--2.46; ALD patients *vs.* non-alcoholics: OR = 1.37, 95%CI 0.92--2.04) ([**Figure 2**](#pone-0054188-g002){ref-type="fig"}). However, a significant association was observed in the homozygous genotype comparison (c2c2 *vs.* c1c1: OR = 3.12, 95%CI 1.91--5.11) when ALD patients were compared with alcoholics without ALD, which was not observed in other genotypes contrasts. In regard with the genotypes contrast between ALD patients and non-alcoholics, no significant association was detected in any genetic model (c2c2 *vs.* c1c1: OR = 1.83, 95%CI 0.80--4.21; c2c2/c2c1 *vs.* c1c1: OR = 1.48, 95%CI 0.93−2.34).

![Meta-analysis for *CYP2E1 Pst I/Rsa I* polymorphism and the risk of ALD (allele c2 *vs.* c1).\
(a) ALD patients *vs.* alcoholics without ALD; (b) ALD patients *vs.* non-alcoholics. Each study was shown by a point estimate of the effect size (OR) (size inversely proportional to its variance) and its 95% confidence interval (95%CI) (horizontal lines). The white diamond denotes the pooled OR.](pone.0054188.g002){#pone-0054188-g002}

Due to the ethnicity-related distinct discrepancy of allele distribution in non-alcoholics (20.4% and 2.7% in Asians and in Caucasians, respectively) ([**Figure 3**](#pone-0054188-g003){ref-type="fig"}), we then made subgroup analysis based on ethnicity. The results revealed that c2c2 genotype was also significantly associated with increased risk of ALD in Asians (c2c2 *vs.* c1c1: OR = 4.11, 95%CI 2.32--7.29), while significant associations were also observed in Caucasians (c1c2 *vs.* c1c1: OR = 1.63, 95%CI 1.05--2.53; c2c2/c1c2 *vs.* c1c1: OR = 1.58, 95%CI 1.04--2.42) when ALD patient were compared with alcoholics without ALD. However, no significant association was also observed in Asians or Caucasians when ALD patients were compared with no-alcoholics (**[Table S2](#pone.0054188.s002){ref-type="supplementary-material"}**).

![Frequencies of the minor allele (c2 allele) of the *CYP2E1 Pst I/Rsa I* polymorphism among control subjects stratified by ethnicity.](pone.0054188.g003){#pone-0054188-g003}

As ALD contains many types of histological forms, including steatosis, hepatisis, fibrosis, and cirrhosis, we then investigated the associations between *CYP2E1 Pst I/Rsa I* polymorphism and the risks of clearly defined alcoholic liver cirrhosis (ALC). As shown in **[Table S3](#pone.0054188.s003){ref-type="supplementary-material"}**, no significant association was observed between *CYP2E1 Pst I/Rsa I* polymorphism and ALC risks in Asians (c2 *vs.* c1, OR = 1.00, 95%CI 0.67--1.49; c2c2/c2c1 *vs.* c1c1, OR = 0.97, 95%CI 0.60--1.57) as well as in Caucasians (c2 *vs.* c1, OR = 1.06, 95%CI 0.63--1.79; c2c2/c2c1 *vs.* c1c1, OR = 1.19, 95%CI 0.69--2.06) when ALC patients were compared with alcoholics without ALD. However, the polled results of the studies, in which cases were composed by several types of ALD patients including steatosis, hepatisis, fibrosis, and cirrhosis, showed significant associations in Asians (c2 *vs.* c1, OR = 4.95, 95%CI 3.55--6.89; c2c2/c2c1 *vs.* c1c1, OR = 4.63, 95%CI 1.75--12.26) and in Caucasians (c2 *vs.* c1, OR = 2.58, 95%CI 1.42--4.67; c2c2/c2c1 *vs.* c1c1, OR = 2.58, 95%CI 1.37--4.87) (**[Table S3](#pone.0054188.s003){ref-type="supplementary-material"}**).

To investigate whether there was difference in the association between *CYP2E1 Pst I/Rsa I* polymorphisms and ALD risks in men and women, we then combined the results of studies in which only male subjects were enrolled. Meta-analysis for the association between CYP2E1 *Pst I/Rsa I* polymorphism and the risk of ALD in male subjects were shown in **[Table S4](#pone.0054188.s004){ref-type="supplementary-material"}**. As shown in **[Table S4](#pone.0054188.s004){ref-type="supplementary-material"}**, no significant association was detected in any comparisons.

Results of pooled analysis on the associations between *CYP2E1 Dra I* polymorphism and the risk of ALD were shown in **[Table S5](#pone.0054188.s005){ref-type="supplementary-material"} and** [**Figure 4**](#pone-0054188-g004){ref-type="fig"}. The combined results showed no significant association between *CYP2E1 Dra I* polymorphism and the risk of ALD (ALD patients *vs.* alcoholics without ALD: d1 *vs.* d2, OR = 1.09, 95%CI 0.80--1.48; d1d1/d1d2 *vs*. d2d2, OR = 1.00, 95% CI 0.75--1.33; ALD patients *vs.* non-alcoholics: d1 *vs.* d2, OR = 1.13, 95%CI 0.77--1.66; d1d1/d1d2 *vs.* d2d2: OR = 1.13, 95% CI 0.76--1.70). We further analyzed the relationship between *CYP2E1 Dra I* polymorphism and the risks of ALC. Again, the pooled results revealed no significant association (**[Table S5](#pone.0054188.s005){ref-type="supplementary-material"}**).

![Meta-analysis for *CYP2E1 Dra I* polymorphism and the risk of ALD in Caucasians (d1 *vs.* d2).\
(a) ALD patients *vs.* alcoholics without ALD; (b) ALD patients *vs.* non-alcoholics. Each study was shown by a point estimate of the effect size (OR) (size inversely proportional to its variance) and its 95% confidence interval (95%CI) (horizontal lines). The white diamond denotes the pooled OR.](pone.0054188.g004){#pone-0054188-g004}

Heterogeneity Source and Sensitivity Analysis {#s3c}
---------------------------------------------

The between-study heterogeneity was significant in the analyses of association between *CYP2E1 Pst I/Rsa I* polymorphism and the risk of ALD in worldwide population (*I^2^\>50% in most comparisons*). Subgroup meta-analysis has been used as a common method for exploring the heterogeneity [@pone.0054188-Song1]. The heterogeneity test of the subgroup of Asians and Caucasians showed much lower heterogeneity existed in the analyses of association between *CYP2E1 Pst I/Rsa I or Dra I* polymorphisms and the risk of ALD in Caucasians, which suggested that ethnicity might be an important contributor to heterogeneity. The heterogeneity test in the subgroup analyses based on the types of ALD showed that lower heterogeneity in the analysis of the association between *CYP2E1 Pst I/Rsa I* polymorphism and ALC risks, indicating that types of ALD might be another source of the between study heterogeneity. Sensitivity analysis was performed by sequential omission of individual studies in every comparison, and the data showed that no study significantly influenced the pooled effects by omitting any single study. For the comparisons between ALD patients and non-alcoholics, the exclusion of the studies deviated form HWE did not change the results significantly.

Publication Bias {#s3d}
----------------

Begg's funnel plots were generated to assess publication bias. The Egger's test was performed to statistically evaluate funnel plot symmetry. Potential publication bias was detected by Egger's test for the comparisons between c2 *vs.* c1, c1c2 *vs.* c1c1, and c2c2/c2c1 *vs.* c1c1 (*P* = 0.025, 0.036, and 0.020, respectively) when ALD patients were compared with alcoholics without ALD in Asians. No significant publication bias was detected in any other comparisons (P~value~ *\>* 0.05 in both Egger's regression and Begg's rank correlation tests).

Discussion {#s4}
==========

ALD is a multifactorial process involving several mechanisms, in which oxidative stress may play an important role [@pone.0054188-Lu2]. Many pathways have been suggested to be associated with ethanol-induced oxidative stress. Among them, the activation of CYP2E1 appears to be a major contributor. It has been found that ethanol -induced liver injury and lipid peroxidation was correlated well with the CYP2E1 levels [@pone.0054188-Castillo1]--[@pone.0054188-French1]. Furthermore, CYP2E1 inhibitors significantly blocked the lipid peroxidation and ameliorated the pathologic changes in ethanol-treated animals [@pone.0054188-Zeng1], [@pone.0054188-Lu1], [@pone.0054188-Gouillon1], [@pone.0054188-Morimoto1], while CYP2E1 over-expressing mice displayed higher transaminase activities and histological features of liver injury when compared with the control mice [@pone.0054188-Morgan1]. All these studies support the critical roles of CYP2E1 in the etiology of ALD. Thus, the *CYP2E1* functional polymorphisms including *Pst I/Rsa I or Dra I* polymorphisms might be associated with the ALD risks of individuals. Unfortunately, previous epidemiological studies conducted in the past 20 decades have yielded conflicting results, ranging from strong association to no links. Because of the above-mentioned conflicting results from relatively small sample size which might be underpowered to detect the potential effects, a meta-analysis might be an appropriate approach to obtain a more definitive conclusion.

In the current study, we made a comprehensive literature search and a total of 27 and 9 studies were finally included for the analysis of the associations between the *CYP2E1 Pst I/Rsa I* polymorphisms and the risk of ALD, and between *CYP2E1 Dra I* polymorphism and the risk of ALD, respectively. The pooled results showed that c2c2 genotype was significantly associated with increased risk of ALD in Asians (**[Table S2](#pone.0054188.s002){ref-type="supplementary-material"}**). These data were well consistent with many previous studies [@pone.0054188-Liu1], [@pone.0054188-Tanaka1], [@pone.0054188-Zhou1]. Another important finding was that a significant association between the *CYP2E1 Pst I/Rsa I* polymorphism and the ALD risk was also found in Caucasians (c1c2 *vs.* c1c1: OR = 1.63, 95%CI 1.05--2.53; c2c2/c1c2 *vs.* c1c1: OR = 1.58, 95%CI 1.04--2.42), although many pervious studies reported no association [@pone.0054188-Parsian1], [@pone.0054188-Lorenzo1], [@pone.0054188-Vidal1], [@pone.0054188-Burim1], [@pone.0054188-Frenzer1], [@pone.0054188-Wong1], [@pone.0054188-Rodrigo1], [@pone.0054188-Agndez1], [@pone.0054188-Carr2], [@pone.0054188-IngelmanSundberg1]. The relatively small sample size in individual studies might cover the potential association, as the frequency of c2 allele in Caucasians was much lower than that in Asians (20.4% *vs.* 2.7% in Asians and Caucasians, respectively) ([**Figure 3**](#pone-0054188-g003){ref-type="fig"}). In contrast to the significant association between *CYP2E1 Pst I/Rsa I* polymorphism and the risk of ALD, no significant association was observed between *CYP2E1 Dra I* polymorphism and the risk of ALD, although the frequency of the *Dra I* polymorphism was about 3-fold of that of the *Pst I/Rsa I* polymorphism in Caucasians (2.7% *vs.* 9.8% in Caucasians in this study) [@pone.0054188-Stephens1].

Zintzaras *et al.* performed a meta-analysis to evaluate the association between the polymorphisms of ethanol-metabolizing enzymes including *CYP2E1 Pst I/Rsa I* polymorphism and the risk of ALD [@pone.0054188-Zintzaras1]. In that study, 8 studies were included for the association assay. The authors evaluated the association of the mutant allele with ALC risks, and the results showed that c2 allele was not significantly associated with the ALC risks (worldwide population: OR = 1.13, 95%CI 0.76--1.68; Caucasians: OR = 1.58, 95%CI 0.76--3.28; Asians: OR = 0.97, 95%CI 0.58--1.62). In the current study, a total of 27 studies were included in the analysis, and the combined results showed a significant association in the genotype contrasts in Asians (c2c2 *vs.* c1c1, OR = 4.11, 95%CI 2.32--7.29) as well as in Caucasians (c2c2/c1c2 *vs.* c1c1, OR = 1.58, 95%CI 1.04--2.42) (**[Table S2](#pone.0054188.s002){ref-type="supplementary-material"}**). However, the subgroup analysis on the association between *CYP2E1 Pst I/Rsa I* polymorphism and ALC risks in the current meta-analysis showed similar results to those obtained in the study by Zintzaras *et al.* (Caucasians: OR = 1.26, 95%CI 0.56--2.85; Asians: OR = 1.00, 95%CI 0.67--1.49) (**[Table S3](#pone.0054188.s003){ref-type="supplementary-material"}**). These results suggested that *CYP2E1 Pst I/Rsa I* polymorphism might be not significantly associated with the ALC risks, but might be significantly associated with other types of ALD. In fact, ALD represents a spectrum of clinical illness and morphological changes that range from alcoholic fatty liver (AFL) to hepatic inflammation and necrosis (alcoholic hepatitis, AH) to progressive fibrosis (AF) and cirrhosis [@pone.0054188-Gramenzi1]. It may be speculated that the *CYP2E1 Pst I/Rsa I* polymorphism might be significantly associated with the earlier liver damages such as AFL and AH, but not with the advanced ALD (ALC), which need to be evaluated in the future studies. This meta-analysis firstly addressed the association between *CYP2E1 Dra I* polymorphism and the risk of ALD, but no significant association was found based on 9 studies performed in Caucasians.

One of the most characteristic features that distinguish CYP2E1 from other ethanol metabolizing enzymes is its inducibility. Some studies demonstrated that ethanol could prevent the decomposition of CYP2E1 protein without influencing the mRNA levels [@pone.0054188-Carroccio1], [@pone.0054188-Eliasson1]; while other studies proposed that ethanol could activate CYP2E1 synthesis [@pone.0054188-Badger1]. It is possible that transcriptional, posttranscriptional and posttranslational events may all take effects in ethanol-induced activation of CYP2E1. As ethanol could activate CYP2E1 by stabilization or increasing synthesis, the mRNA levels are not systematically enhanced. Therefore, detection of CYP2E1 activity *in vivo* would be a more reliable method for the evaluation of CYP2E1 status, and may be helpful to evaluate the association of *CYP2E1* polymorphisms and the risk of ALD. If subjects with c2c2/c1c2 genotypes have higher CYP2E1 activity, then a solid conclusion about the association between *CYP2E1 Pst I/Rsa I* polymorphism and ALD risk, would be more rational and reliable, as these persons would be more susceptive to ALD. However, this information is limited in the literature. A preliminary study on the elimination of acetaminophen, which was metabolized mainly by CYP2E1, suggested that individuals with homozygous c2c2 genotypes exhibited higher CYP2E1 activity than individuals with c1c1 or c1c2 genotypes [@pone.0054188-Tsutsumi1]. However, several other studies in which the activity of CYP2E1 was detected using chlorzoxazone metabolism have revealed that subjects with c2 alleles did not have enhanced CYP2E1 activity [@pone.0054188-Lucas2], [@pone.0054188-Marchand1]. Anyway, much more studies were still needed to clarify the relationship between the *CYP2E1 Pst I/Rsa I* polymorphisms and the activity of CYP2E1 *in vivo*.

Despite clear strengths of our study including the larger sample size and comprehensive literature search, it dose have some limitations. Firstly, the present meta-analysis was based on unadjusted effect estimates and CIs, since most studies did not provide the adjusted OR and 95%CI controlling for potential confounding factors. Secondly, moderate to higher heterogeneity existed for the analyses especially for the subgroup of Asians. Thirdly, it has been well known that ALD is a multifactor diseases, however, the effects of gene-gene and gene-environment interactions were not addressed in this meta-analysis, and thus the potential roles of the above gene polymorphism may be masked or magnified by other gene-gene/gene-environment interactions.

In summary, this meta-analysis systematically analyzed the association between the *CYP2E1 Pst I/Rsa I* and *Dra I* polymorphisms and the risk of ALD. The combined results showed that *CYP2E1 Pst I/Rsa I* polymorphism might be not significantly associated with advanced form of ALD (ALC), but might be significantly associated with other form of ALD such as steatosis, hepatisis, fibrosis. Furthermore, *CYP2E1 Dra I* polymorphism might be not significantly associated with ALD risks. Since potential confounders could not be ruled out completely, further studies are needed to confirm these results.
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